Jump to content

Pateclizumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 21:03, 17 November 2016 (Updating {{infobox_drug}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'Watchedfields') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pateclizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Targetlymphotoxin alpha
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6436H9910N1710O2004S44
Molar mass144.7 kDa g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pateclizumab is an immunomodulator. It binds to lymphotoxin alpha.[1][2]

This drug was developed by Genentech/Roche.

References

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.



Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pateclizumab&oldid=750103912"